CPA
PRAX icon

Capital Performance Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Capital Performance Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22
Closed -$1.27K – 2026
2024
Q3 		$1.27K Buy
+22
New +$1.19K ﹤0.01% 1788

Other funds holding PRAX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Performance Advisors's PRAX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Praxis Precision Medicines (PRAX) in Q4 2024, closing a stake of 22 shares — an estimated $1.27K sold.

Capital Performance Advisors first reported a position in PRAX in Q3 2024 and held it in 1 quarter. The position peaked at $1.27K in Q3 2024. 162 funds tracked by Wall St. Rank hold PRAX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Praxis Precision Medicines position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 22 Praxis Precision Medicines shares in Q4 2024, an estimated $1.27K.
  • Capital Performance Advisors first reported a position in Praxis Precision Medicines in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Praxis Precision Medicines position peaked at $1.27K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.